NCT01349920
Source recordAI-normalized
An Open Label Study to Discover Biomarkers of Intestinal Mucosal Healing in Crohn's Disease (CD)
This study will evaluate biomarkers that reflect changes in gut mucosal status during therapy with infliximab and determine whether changes in the levels of the selected biomarkers can be used to predict endoscopically assessed gut mucosal status changes.
AI analysis
Indication: Crohn Disease
Modality: monoclonal antibody
Target: Infliximab
Sponsor: Merck Sharp & Dohme LLC
Source URL: ClinicalTrials.gov
Source updated: Oct 15, 2018
Ingested: May 22, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Infliximab
View original source fields
Condition raw: Crohn Disease
Condition normalized: Crohn Disease
Modality raw: monoclonal antibody
Modality normalized: monoclonal antibody
Target raw: Infliximab
Target normalized: Infliximab